These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31639790)

  • 1. Efficacy of Oral Nicorandil to Prevent Contrast-Induced Nephropathy in Patients with Chronic Renal Dysfunction Undergoing an Elective Coronary Procedure.
    Fan Z; Li Y; Ji H; Jian X
    Kidney Blood Press Res; 2019; 44(6):1372-1382. PubMed ID: 31639790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
    Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
    Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
    Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
    Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study).
    Ko YG; Lee BK; Kang WC; Moon JY; Cho YH; Choi SH; Hong MK; Jang Y; Kim JY; Min PK; Kwon HM;
    Yonsei Med J; 2013 Jul; 54(4):957-64. PubMed ID: 23709432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive Effects of Nicorandil Against Contrast-Induced Nephropathy in Patients With Moderate Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
    Zhang P; Li WY; Yang SC; Fu NK; Liu XG; Zhang X; Cong HL; Lin WH; Tian FS; Lu CZ; Zhang J
    Angiology; 2020 Feb; 71(2):183-188. PubMed ID: 30987432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial.
    Abdollahi Moghaddam A; Baradaran Rahimi V; Morovatdar N; Rezaee R; Babalhekam SA
    Int Urol Nephrol; 2023 Sep; 55(9):2327-2334. PubMed ID: 36881267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimetazidine Prevention of Contrast-Induced Nephropathy in Coronary Angiography.
    Liu W; Ming Q; Shen J; Wei Y; Li W; Chen W; Xu Y
    Am J Med Sci; 2015 Nov; 350(5):398-402. PubMed ID: 26445302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.
    Yusuf J; Prakash G; Safal S; Mehta V; Mukhopadhyay S
    Coron Artery Dis; 2024 May; 35(3):186-192. PubMed ID: 38411168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive effect of nicorandil on contrast-induced nephropathy: a meta-analysis of randomised controlled trials.
    Li S; Wang L; Liu Y; Hu Q
    Intern Med J; 2018 Aug; 48(8):957-963. PubMed ID: 29740934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nicorandil on the prevention of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention.
    Zhang X; Yang S; Zhang P; Fu N
    Coron Artery Dis; 2020 May; 31(3):284-288. PubMed ID: 31658134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
    Fu N; Yang S; Zhang J; Zhang P; Liang M; Cong H; Lin W; Tian F; Lu C
    Int Urol Nephrol; 2018 Jan; 50(1):105-112. PubMed ID: 29071556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of contrast-induced nephropathy after coronary angiography in patients with chronic kidney disease.
    Alharazy SM; Kong N; Saidin R; Gafor AH; Maskon O; Mohd M; Zakaria SZ
    Angiology; 2014 May; 65(5):436-42. PubMed ID: 23580616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Alprostadil on the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of 36 Randomized Controlled Trials.
    Xie J; Jiang M; Lin Y; Deng H; Li L
    Angiology; 2019 Aug; 70(7):594-612. PubMed ID: 30669852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
    Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preprocedure and Postprocedure Predictive Values of Serum β2-Microglobulin for Contrast-Induced Nephropathy in Patients Undergoing Coronary Computed Tomography Angiography: A Comparison With Creatinine-Based Parameters and Cystatin C.
    Li S; Zheng Z; Tang X; Peng L; Luo Y; Dong R; Zhao Y; Liu J
    J Comput Assist Tomogr; 2015; 39(6):969-74. PubMed ID: 26248154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.